Comparing the current results to its competitors, Gain Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 18.45 %, recorded in the same quarter.
Gain Therapeutics Inc's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic research institutions, governmental agencies, and public and private research organizations worldwide. Competitors often possess greater financial resources and expertise in areas such as research and development, manufacturing, preclinical testing, clinical trials, regulatory approvals, and marketing. Smaller or early-stage companies may also present competition, particularly through collaborations with larger firms. Competition extends to recruiting qualified personnel, establishing clinical trial sites, patient enrollment, and acquiring complementary technologies. While the company is not aware of others pursuing the same therapeutic approach to protein folding disorders, it recognizes competitors developing products for similar target indications, including Vanqua Bio, BIAL, and Caraway Therapeutics, which focus on GBA-PD using small molecules.
April 10, 2025
: Gain Therapeutics, Inc. (NASDAQ: GANX) has garnered attention at the AD/PD 2025 conference with its recent oral presentation on the promising preclinical data of GT-02287. The data highlights the disease-modifying potential of this investigational therapy in models of GBA1 and idiopathic Parkinson s disease. Additionally, the biopharmaceutical company disclosed the design of its upcoming Phase 1b clinical trial and provided an update on patient enrollment, signaling a strategic advancement in its clinical development program. Gain s equity stands at 22.93 million shares outstanding, with a current stock price of $1.65.Parkinson s disease (PD) is a debilitating neurodegenerative disorder characterized by th...
September 19, 2024
In an exciting advancement for Parkinson’s disease treatment, Gain Therapeutics, Inc. (Nasdaq: GANX) has announced the presentation of groundbreaking preclinical data for its lead drug candidate, GT-02287. These findings will be showcased at the upcoming Neuroscience 2024 conference, taking place from October 5-9 in Chicago, Illinois. Notably, the company will present two late-breaking abstracts, shedding light on the promising therapeutic potential of GT-02287, particularly in Parkinson s patients with or without GBA1 mutations.Gain Therapeutics, a clinical-stage biotechnology company at the forefront of developing allosteric small molecule therapies, has made significant strides in its ongoing research t...
August 29, 2024
In the realm of medicinal science, momentous developments often bring forth hope and anticipation. Such is the case with the recent commendable pronouncement from Gain Therapeutics Inc regarding the promising results derived from the Phase 1 clinical trial of their novel medicinal concoction, GT-02287. This assay, a pioneering endeavour, focuses on targeting the glucocerebrosidase enzyme (GCase) for the treatment of Parkinson s Disease.The aforementioned periodical trial has yielded fruitful results pertaining to safety, tolerability, pharmacokinetics, and target engagement of GT-02287, thereby instilling confidence in the therapeutic potential of this innovation. The study meticulously scrutinised a cohort ...
February 6, 2024
Pharmaceutical innovation has once again shown its potential to redefine medical possibilities. Ground-breaking research from Gain Therapeutics has revealed that their therapeutic agent, GT-02287, has demonstrated the potential to completely restore motor function in Parkinson s disease mouse models. These compelling results were recently unveiled at the 20th WORLDSymposium.Parkinson s disease is a neurodegenerative disorder that significantly affects motor function, giving rise to symptoms such as tremors, stiffness, and movement difficulty. Currently, treatments for the disease only manage the symptoms, but do not halt the disease progression. This innovative study from Gain Therapeutics might just be the ...
December 1, 2023
Press Release: Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model In an exciting development, Gain Therapeutics has recently revealed preclinical data demonstrating the restoration of enzymatic function using novel allosteric regulators in a model of GM1 gangliosidosis. This breakthrough discovery offers new hope for individuals suffering from this rare and debilitating inherited disorder. GM1 gangliosidosis is a lysosomal storage disorder caused by the deficiency of the enzyme beta-galactosidase (β-Gal). This deficiency leads to the accumulation of harmful substances called GM1 gangliosides within the c...
Kamada Ltd is a biopharmaceutical company that operates on a business model centered around developing and commercializing specialty plasma-derived therapeutics. The company focuses on leveraging its expertise in proprietary protein purification technology and plasma collection to produce and deliver high-quality therapeutic products. Kamada aims to address unmet medical needs in various therapeutic areas, providing innovative treatment options to patients worldwide.
Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.
Ibio Inc is a plant-based biologics company that focuses on the development and manufacturing of therapeutic proteins. They utilize their proprietary plant-based expression system to produce biotherapeutics quickly and cost-effectively. By leveraging their platform, Ibio aims to address unmet medical needs and provide affordable and accessible treatments to patients worldwide.
Sources:
Gain Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Gain Therapeutics inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
